Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333177 · ClinicalTrials.gov registry record · Phase 4
Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
NCT00333177 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 92 participants.
The verdict
NCT00333177, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.
Interventions
- BEHAVIORAL Cognitive remediation training (CT)
- BEHAVIORAL Healthy behavior training (HBT)
- DRUG Risperidone, administered orally (Oral Ris)
- DRUG Risperidone, administered via injection (RLAI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2006-03 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333177
The ClinicalTrials.gov registry entry for NCT00333177 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cognitive remediation training (CT) is the first listed.
NCT00333177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00333177 about?
NCT00333177 is a clinical study titled "Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia". This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia.
What is the current status of trial NCT00333177?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2006-03. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00333177?
The interventions under investigation include: Cognitive remediation training (CT) (BEHAVIORAL), Healthy behavior training (HBT) (BEHAVIORAL), Risperidone, administered orally (Oral Ris) (DRUG), Risperidone, administered via injection (RLAI) (DRUG).
Who is sponsoring clinical trial NCT00333177?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.